Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation.

Abstract excerpt

Targeted therapy with a combination of dabrafenib and trametinib has been developed and widely used for treatment of melanoma. However, data regarding its safety and efficacy in Japanese patients with malignant melanoma are limited. A post-marketing surveillance (PMS) study was conducted to investigate the safety and efficacy of combination therapy in a Japanese clinical setting with a surveillance period of June...

Topics

Join the communities discussing this publication.

• Antineoplastic Combined Chemotherapy Protocols
• East Asian People
• Fever
• Melanoma
• Melanoma, Cutaneous Malignant